TY  - JOUR
AU  - Qiao, Jingxin
AU  - Li, Yue-Shan
AU  - Zeng, Rui
AU  - Liu, Feng-Liang
AU  - Luo, Rong-Hua
AU  - Huang, Chong
AU  - Wang, Yi-Fei
AU  - Zhang, Jie
AU  - Quan, Baoxue
AU  - Shen, Chenjian
AU  - Mao, Xin
AU  - Liu, Xinlei
AU  - Sun, Weining
AU  - Yang, Wei
AU  - Ni, Xincheng
AU  - Wang, Kai
AU  - Xu, Ling
AU  - Duan, Zi-Lei
AU  - Zou, Qing-Cui
AU  - Zhang, Hai-Lin
AU  - Qu, Wang
AU  - Long, Yang-Hao-Peng
AU  - Li, Ming-Hua
AU  - Yang, Rui-Cheng
AU  - Liu, Xiaolong
AU  - You, Jing
AU  - Zhou, Yangli
AU  - Yao, Rui
AU  - Li, Wen-Pei
AU  - Liu, Jing-Ming
AU  - Chen, Pei
AU  - Liu, Yang
AU  - Lin, Gui-Feng
AU  - Yang, Xin
AU  - Zou, Jun
AU  - Li, Linli
AU  - Hu, Yiguo
AU  - Lu, Guang-Wen
AU  - Li, Wei-Min
AU  - Wei, Yu-Quan
AU  - Zheng, Yong-Tang
AU  - Lei, Jian
AU  - Yang, Shengyong
TI  - SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model
JO  - Science
VL  - 371
IS  - 6536
SN  - 0036-8075
CY  - Cambridge, Mass.
PB  - Moses King
M1  - PUBDB-2021-04550
SP  - 1374 - 1378
PY  - 2021
AB  - Vaccines are an important tool in the fight against COVID-19, but developing antiviral drugs is also a high priority, especially with the rise of variants that may partially evade vaccines. The viral protein main protease is required for cleaving precursor polyproteins into functional viral proteins. This essential function makes it a key drug target. Qiao et al. designed 32 inhibitors based on either boceprevir or telaprevir, both of which are protease inhibitors approved to treat hepatitis C virus. Six compounds protected cells from viral infection with high potency, and two of these were selected for in vivo studies based on pharmokinetic experiments. Both showed strong antiviral activity in a mouse model.
LB  - PUB:(DE-HGF)16
C6  - pmid:33602867
UR  - <Go to ISI:>//WOS:000636043400052
DO  - DOI:10.1126/science.abf1611
UR  - https://bib-pubdb1.desy.de/record/471682
ER  -